2. Academic Validation
  3. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel

Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel

  • Nanomedicine (Lond). 2015;10(7):1139-47. doi: 10.2217/nnm.14.194.
Hirofumi Hanaoka 1,  Takahito Nakajima,  Kazuhide Sato,  Rira Watanabe,  Yen Phung,  Wei Gao,  Toshiko Harada,  Insook Kim,  Chang H Paik,  Peter L Choyke,  Mitchell Ho,  Hisataka Kobayashi
Affiliations

Affiliation

  • 1 Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Building 10, Room B3B69, MSC1088, Bethesda, MD 20892, USA.
PMID: 25929570 DOI: 10.2217/nnm.14.194
Abstract

Aim: Effectiveness of Glypican-3 (GPC3)-targeted photoimmunotherapy (PIT) combined with the nanoparticle albumin-bound paclitaxel (nab-paclitaxel) for hepatocellular carcinoma was evaluated.

Materials & methods: GPC3 expressing A431/G1 cells were incubated with a phthalocyanine-derivative, IRDye700DX (IR700), conjugated to an anti-GPC3 antibody, IR700-YP7 and exposed to near-infrared light. Therapeutic experiments combining GPC3-targeted PIT with nab-paclitaxel were performed in A431/G1 tumor-bearing mice.

Results: IR700-YP7 bound to A431/G1 cells and induced rapid target-specific necrotic cell death by near-infrared light exposure in vitro. IR700-YP7 accumulated in A431/G1 tumors. Tumor growth was inhibited by PIT compared with nontreated control. Additionally, PIT dramatically increased nab-paclitaxel delivery and enhanced the therapeutic effect.

Conclusion: PIT targeting GPC3 combined with nab-paclitaxel is a promising method for treating hepatocellular carcinoma.

Keywords

Glypican-3; hepatoma; monoclonal antibody; nab-paxlitaxel; nanodelivery; photocyanine dye; photoimmunotherapy.

Figures
Products